Bronchogen
A short synthetic Khavinson bioregulator peptide positioned to support bronchial epithelium and mucociliary function in age-related and chronic respiratory decline.
Bronchogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, marketed as a 'bronchial bioregulator' for respiratory epithelium and ciliated-airway support in COPD, chronic bronchitis, and age-related loss of mucociliary clearance. It is the defined-sequence synthetic counterpart to Chonluten, a bovine bronchial polypeptide extract, and sits within the Khavinson short-peptide family alongside Pinealon, Thymogen, Vilon, Livagen, and Epitalon. Evidence is limited to Russian in vitro cell-culture work, small rodent lung-injury studies, and uncontrolled observational case series; it is not approved or guideline-recognized outside Russia.
Class
Synthetic short-peptide bioregulator (Khavinson tetrapeptide)
Routes
Oral capsule, Sublingual, Subcutaneous (reconstituted synthetic peptide)
Category
Longevity & Bioregulators
Researched benefits
What it's studied for
Respiratory tissue repair
Positioned to support regeneration of bronchial epithelium. Russian in vitro work on ciliated epithelial cultures describes morphological improvement in cilia structure after exposure; evidence is preclinical and unreplicated in Western literature.
Improved bronchial function
Claimed to enhance mucociliary index and airway epithelial function. Uncontrolled observational series in elderly patients report subjective improvements in dyspnoea, cough, and sputum clearance with modest spirometry changes.
Support for chronic respiratory conditions
Marketed as an adjunct in COPD, chronic bronchitis, and post-infective respiratory dysfunction, particularly in older adults; framed as an experimental add-on rather than a substitute for inhaled therapy.
Mucosal membrane normalization
The Khavinson framework proposes preferential up-regulation of genes tied to ciliogenesis, surfactant production, tight-junction proteins, and mucin programmes, theoretically normalizing airway mucosa. This remains a chromatin-modulation hypothesis, not a measured effect.
Mechanism
How it works
Bronchogen's proposed mechanism is the standard Khavinson short-peptide bioregulator model applied to bronchial and respiratory epithelium. The framework proposes a three-stage mechanism: passive membrane permeation, nuclear import by diffusion, and sequence-selective chromatin interaction that produces tissue-appropriate gene-expression changes. At roughly 430-459 daltons, the peptide is small and sufficiently polar to cross phospholipid bilayers passively, and Khavinson-group tritiated-peptide biodistribution studies reported rapid uptake into lung, liver, brain, and thymus within minutes of dosing.
The tissue-selectivity claim holds that the peptide preferentially accumulates in bronchial tissue, explaining a respiratory-selective effect. The supporting data are radiolabel-uptake measurements in bulk tissue homogenates that did not separate intact peptide from catabolite pools. Modern methods — LC-MS/MS intact-peptide quantification, dose-matched immunohistochemistry, single-cell transcriptomics of airway epithelium — have not been applied to Bronchogen in English-indexed literature, so bronchial selectivity remains inferred rather than demonstrated.
Once inside the cell, the framework proposes the peptide diffuses through nuclear pores and makes sequence-selective contacts with exposed DNA and histone tails, preferentially decondensing silenced chromatin carrying epithelial-regeneration genes. No genome-wide ChIP-seq, ATAC-seq, or CUT&RUN data support this for any short Khavinson peptide. No GPCR, nuclear receptor, or enzyme target has been identified; Bronchogen does not bind beta2-adrenoceptors, muscarinic receptors, or leukotriene receptors, unlike evidence-graded respiratory drugs.
A more conservative interpretation treats Bronchogen simply as a rapidly absorbed mixture of four amino acids (alanine, glutamate, aspartate, and leucine or proline) that may provide substrate for protein synthesis in fast-turnover epithelium or non-specific amino-acid signalling. Under this framing any comparable amino-acid mixture would be mechanistically equivalent, which makes the specificity claim for the defined sequence difficult to defend under rigorous pharmacological testing.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
For synthetic lyophilised peptide only (not the commercial capsule): reconstitute a 5 mg vial with 2 mL bacteriostatic water to yield 2.5 mg/mL, injecting the water slowly down the vial wall and allowing passive dissolution over 5-10 minutes. At 2.5 mg/mL: a 2 mg dose = 0.8 mL (80 units on a U100 insulin syringe), 2.5 mg = 1.0 mL (100 units), 5 mg = 2.0 mL. Store reconstituted at 2-8 C (not frozen); stability ~28 days; discard if cloudy or with particulate.
Beginner
- Dose
- 1 capsule (20 mg nominal)
- Frequency
- Once daily
- Timing
- Sublingual (~60 s under tongue) or oral on empty stomach 30-45 min before breakfast; autumn entry is the traditional starting point
- Duration
- 10 consecutive days, then stop
- Route
- Oral / sublingual
Use only third-party HPLC-verified product. Track home peak flow, dyspnoea VAS, cough, and sputum. Continue all existing inhaled therapy; do not expect transformative effects. Minimum 60-day washout before repeating.
Intermediate
- Dose
- 20 mg oral/sublingual OR 2-5 mg SC
- Frequency
- Once daily
- Timing
- Twice-yearly cycling, autumn (pre-winter) and spring (allergy/recovery season), at least 5-6 months between starts
- Duration
- 10 consecutive days per cycle
- Route
- Oral / sublingual or subcutaneous (reconstituted peptide)
Rotate within a multi-bioregulator programme (Thymogen, Epitalon, Pinealon, Livagen). Coordinate cycles with clinical spirometry if COPD; keep a peptide log with dose, source, lot, and endpoints. Do not substitute for clinic-prescribed therapy.
Advanced
- Dose
- 20 mg oral/sublingual OR 5 mg SC daily
- Frequency
- Once daily during 10-day windows within an annual rotation
- Timing
- Month 1 Bronchogen; Months 2-3 washout; Month 4 Thymogen; Month 7 Epitalon; Month 10 Bronchogen spring cycle; remaining months washout
- Duration
- 10 days per cycle, twice yearly for Bronchogen
- Route
- Oral / sublingual or subcutaneous
For users with 6+ months bioregulator experience and stable baseline respiratory function. Baseline and annual spirometry, annual CBC/CMP/lipids, and clinician notification if on COPD maintenance therapy. The rotation is an experimental layer on top of an evidence-graded foundation, not a replacement for it.
- The 20 mg oral capsule contains an undisclosed amount of actual peptide; historical vendor disclosures suggest roughly 2-4 mg of the active peptide with the balance as excipients.
- Subcutaneous administration bypasses first-pass hydrolysis and theoretically delivers higher systemic exposure per milligram, though no published PK data quantify the difference.
- The 10-days-on / 60-90-days-off cycling pattern is uniform across the Khavinson tetrapeptide family and is conventional rather than empirically optimised; do not run continuous (year-round) dosing.
- No established maximum dose; do not exceed 20 mg oral or 5 mg SC daily without clinical reason. Intranasal dosing has no Khavinson protocol or PK support for Bronchogen.
- Avoid in significant renal impairment (eGFR <30) and decompensated hepatic disease pending modern PK data. Russian studies typically enrol adults 60+; no paediatric use.
Evidence
Research & clinical studies (4)
Khavinson tritiated short-peptide biodistribution studies
Radiolabelled tetrapeptide was recovered from lung, liver, brain, and thymus within minutes of intraperitoneal or oral dosing, though intact peptide was not separated from catabolite pools.
Chalisova et al. in vitro study of Bronchogen on ciliated bronchial epithelium cultures
Bronchogen exposure was associated with morphological improvement in cilia structure and mucociliary index in cultured ciliated epithelium.
Khavinson et al. observational and preclinical respiratory work on Bronchogen
Small uncontrolled observational series in elderly chronic respiratory disease patients reported subjective improvements in dyspnoea, cough, and sputum clearance with modest spirometry changes.
Kuznik et al. bioregulator peptide research
Contributed to the Khavinson-family evidence base describing short-peptide bioregulator effects, cited alongside the respiratory work on Bronchogen.
Combinations
Stacking & blends
Bronchogen + Chonluten
Layered respiratory bioregulation
Chonluten is the bovine bronchial polypeptide 'parent' extract and Bronchogen its defined-sequence synthetic sibling; the two are listed as a synergistic/compatible respiratory pairing.
Khavinson annual rotation
Multi-tissue bioregulator cycling across a year
Bronchogen (respiratory) is rotated with immune, pineal/anti-aging, brain, and liver bioregulators in 10-day pulses separated by washouts, following the standard Khavinson multi-peptide programme.
Bronchogen + NAC / mucolytics
Symptom support in chronic bronchitis
NAC 600-1200 mg daily has some evidence for chronic bronchitis symptom reduction and alters mucus disulphide chemistry; it layers safely alongside Bronchogen cycles from an interaction standpoint, though neither replaces smoking cessation or prescribed inhaled therapy.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Pregnancy (no reproductive toxicology data)
- Breastfeeding (no excretion/infant safety data)
- Paediatric use under 18 (unquantified developmental effects)
- Active lung cancer or recent history (chromatin-modulation claim unsafe in proliferative lung disease)
- Known hypersensitivity to Bronchogen or any Khavinson bioregulator peptide
- Active respiratory infection (relative)
- Significant renal impairment (eGFR <30) or decompensated hepatic disease (relative, pending PK data)
The reported short-term safety profile in Russian literature is mild, but total documented human exposure is likely only in the low thousands — too small to detect rare serious events — and long-term safety over years of intermittent cycles is uncharacterized. Bronchogen should never replace inhaled maintenance therapy; do not reduce or stop prescribed inhalers to test it. Use HPLC-verified product and monitor baseline and post-cycle spirometry where possible.
FAQ
Bronchogen — common questions
What is Bronchogen and what is it claimed to do?
Bronchogen is a synthetic short peptide (reported as Ala-Glu-Asp-Leu, and described as Ala-Glu-Asp-Pro in overview text) developed by Vladimir Khavinson's St. Petersburg institute as a respiratory bioregulator. It is positioned to support bronchial epithelium regeneration, mucociliary clearance, and respiratory function in elderly patients with COPD, chronic bronchitis, and post-infective dysfunction. It is not FDA/EMA approved and appears in no major respiratory guideline — treat it as an experimental bioregulator.
Does Bronchogen actually help with COPD or chronic bronchitis?
The evidence is thin. Russian uncontrolled observational series report subjective improvements in dyspnoea, cough, and sputum clearance and modest spirometry gains after 20-30 day cycles, but there are no placebo-controlled blinded trials. Reported improvements are equally consistent with placebo, seasonal variation, or concomitant therapy. Evidence-graded COPD priorities remain smoking cessation, bronchodilators, inhaled corticosteroids where indicated, pulmonary rehab, and vaccination.
What is the correct Bronchogen dose?
Khavinson convention is 20 mg oral/sublingual once daily for 10 consecutive days with 60-90 day washouts between cycles. The 20 mg capsule contains an undisclosed amount of peptide (historically ~2-4 mg active). For subcutaneous synthetic peptide, 2-5 mg daily for 10 days is the community pattern. Autumn entry before winter respiratory season is favoured, sometimes with a spring repeat. No dose-ranging trial establishes an optimum.
How does Bronchogen compare to inhalers and evidence-graded therapies?
Inhaled beta2-agonists, corticosteroids, and muscarinic antagonists work through mapped molecular mechanisms with thousands of RCTs. Bronchogen sits at an entirely different level of specification — a chromatin-modulation hypothesis with limited replication. For any serious respiratory disease it can only be an experimental adjunct on top of evidence-graded therapy, never a replacement.
Is Bronchogen safe?
Reported short-term safety is mild (occasional nausea, mild headache, rare rash), but documented human exposure is small and long-term safety is uncharacterized. Pregnancy, breastfeeding, paediatric use, active lung cancer, and active respiratory infection are absolute or strong contraindications. Use HPLC-verified product, monitor spirometry where possible, and work with a pulmonologist if you have chronic respiratory disease.
Can I use Bronchogen while on inhaled therapy?
From an interaction standpoint yes — there are no known pharmacokinetic or pharmacodynamic interactions between Bronchogen and inhaled beta2-agonists, muscarinic antagonists, or corticosteroids. But Bronchogen must never substitute for inhaled maintenance therapy; do not reduce inhalers to test it, and notify your pulmonologist of any bioregulator cycles.
How does Bronchogen compare to other Khavinson peptides?
It is the respiratory-focused member of the family, sibling to Pinealon (brain), Thymogen (immune), Vilon (thymus), Livagen (liver), and Epitalon (pineal/aging), sharing the passive-permeation-plus-chromatin-modulation claim. It is less published in English-indexed literature than Epitalon or Thymogen and occupies a narrower respiratory niche.
Where should I source Bronchogen?
Supply is split between post-Soviet vendors selling 20 mg oral capsules at moderate cost with variable quality control, and international suppliers selling lyophilised synthetic peptide for reconstitution at higher per-mg cost. Require third-party HPLC content confirmation and endotoxin testing, and avoid vendors without certificates of analysis. The oral capsule is the conservative default for first-time users.
